Cargando…
Correction to: Intravitreal aflibercept for diabetic macular edema in real‑world clinical practice in Japan: 24‑month outcomes
Autores principales: | Sugimoto, Masahiko, Handa, Chiharu, Hirano, Kazufumi, Sunaya, Toshiyuki, Kondo, Mineo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803755/ https://www.ncbi.nlm.nih.gov/pubmed/36472690 http://dx.doi.org/10.1007/s00417-022-05917-x |
Ejemplares similares
-
Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes
por: Sugimoto, Masahiko, et al.
Publicado: (2022) -
Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes
por: Shimura, Masahiko, et al.
Publicado: (2022) -
Effects of Intravitreal Aflibercept on Retinal Function and Improvement of Macular Edema Associated With Diabetic Retinopathy
por: Ichio, Atsushi, et al.
Publicado: (2020) -
Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration
por: Ozawa, Yoko, et al.
Publicado: (2023) -
Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
por: Chujo, Shinichiro, et al.
Publicado: (2020)